TrialPath
Recruiting

A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis

NCT07412704 · Bristol-Myers Squibb
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Phase 1/2a, Open-label, First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of BMS-986528 in Participants With Refractory Rheumatoid Arthritis
About this study
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the preliminary evidence of disease-modifying effect of BMS-986528 in participants with refractory, difficult-to-treat rheumatoid arthritis (RA).
Eligibility criteria
Inclusion Criteria \- Adult participants with rheumatoid arthritis (RA) who meet definition of difficult-to-treat. Exclusion Criteria * Juvenile arthritis or onset of inflammatory arthritis before age 18. * Seronegative RA participants in whom polymyalgia rheumatica has not been ruled out. * Active fibromyalgia with pain symptoms or signs that would interfere with joint assessment. * Other protocol-defined Inclusion/Exclusion criteria apply.
Study design
Enrollment target: 84 participants
Allocation: non_randomized
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-09-15
Estimated completion: 2030-09-02
Last updated: 2026-08-24
Interventions
Drug: BMS-986528
Primary outcomes
  • Number of participants with treatment-emergent adverse events (TEAEs) (Up to Week 54)
  • Number of participants with Serious Adverse Events (SAEs) (Up to Week 54)
Sponsor
Bristol-Myers Squibb · industry
Contacts & investigators
ContactBMS Clinical Trials Contact Center www.BMSClinicalTrials.com · contact · Clinical.Trials@bms.com · 855-907-3286
ContactFirst line of the email MUST contain NCT # and Site #. · contact
InvestigatorBristol-Myers Squibb · study_director, Bristol-Myers Squibb
All locations (39)
Local Institution - 0068Not Yet Recruiting
La Jolla, California, United States
Local Institution - 0070Not Yet Recruiting
Loma Linda, California, United States
Local Institution - 0069Not Yet Recruiting
Palo Alto, California, United States
Local Institution - 0050Not Yet Recruiting
Aurora, Colorado, United States
Colorado Blood Cancer InstituteRecruiting
Denver, Colorado, United States
Local Institution - 0055Not Yet Recruiting
South Miami, Florida, United States
Local Institution - 0081Not Yet Recruiting
New York, New York, United States
Local Institution - 0079Not Yet Recruiting
New York, New York, United States
Local Institution - 0066Not Yet Recruiting
Portland, Oregon, United States
Local Institution - 0071Not Yet Recruiting
Philadelphia, Pennsylvania, United States
Local Institution - 0051Withdrawn
DeSoto, Texas, United States
Local Institution - 0048Not Yet Recruiting
Merksem, Flanders, Belgium
Local Institution - 0049Not Yet Recruiting
Leuven, Belgium
Local Institution - 0083Not Yet Recruiting
Aparecida de Goiânia, Goiás, Brazil
Local Institution - 0033Not Yet Recruiting
Porto Alegre, Rio Grande do Sul, Brazil
Local Institution - 0082Not Yet Recruiting
Valinhos, São Paulo, Brazil
Local Institution - 0006Not Yet Recruiting
Beijing, Beijing Municipality, China
Local Institution - 0080Not Yet Recruiting
Guangzhou, Guangdong, China
Local Institution - 0010Not Yet Recruiting
Zhengzhou, Henan, China
Local Institution - 0007Not Yet Recruiting
Nanchang, Jiangxi, China
Local Institution - 0020Not Yet Recruiting
Shanghai, Shanghai Municipality, China
Local Institution - 0001Not Yet Recruiting
Shanghai, Shanghai Municipality, China
Local Institution - 0040Not Yet Recruiting
München, Bavaria, Germany
Charité Research OrganisationRecruiting
Berlin, Germany
Local Institution - 0021Not Yet Recruiting
Cologne, Germany
Local Institution - 0028Not Yet Recruiting
Herne, Germany
St. Josef-Stift SendenhorstRecruiting
Sendenhorst, Germany
Local Institution - 0019Not Yet Recruiting
Rozzano, Milano, Italy
Local Institution - 0017Not Yet Recruiting
Roma, Italy
Local Institution - 0053Not Yet Recruiting
México, Mexico
Local Institution - 0023Not Yet Recruiting
Józefów, Masovian Voivodeship, Poland
Local Institution - 0039Not Yet Recruiting
A Coruña, A Coruña [La Coruña], Spain
Local Institution - 0058Not Yet Recruiting
Córdoba, Córdoba, Spain
Local Institution - 0037Not Yet Recruiting
Bern, Switzerland
Local Institution - 0027Not Yet Recruiting
Geneva, Switzerland
Local Institution - 0060Not Yet Recruiting
Ivano-Frankivsk, Ivano-Frankivsk Oblast, Ukraine
Local Institution - 0064Not Yet Recruiting
Kyiv, Kyiv Oblast, Ukraine
Local Institution - 0063Not Yet Recruiting
Poltava, Poltava Oblast, Ukraine
Local Institution - 0061Not Yet Recruiting
Ternopil, Ukraine
A Study of BMS-986528 in Participants With Refractory Rheumatoid Arthritis · TrialPath